These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Determinants of follow-up in an early intervention program in high-risk babies. deSouza N; Patel V; D'Souza P; Rao HB Indian Pediatr; 2000 Sep; 37(9):986-9. PubMed ID: 10992335 [No Abstract] [Full Text] [Related]
3. The impact of compliance on drug development. Urquhart J Transplant Proc; 1999 Jun; 31(4A):39S. PubMed ID: 10372043 [No Abstract] [Full Text] [Related]
4. Failure to comply: a therapeutic dilemma and the bane of clinical trials. Gibaldi M J Clin Pharmacol; 1996 Aug; 36(8):674-82. PubMed ID: 8877670 [No Abstract] [Full Text] [Related]
5. Patient compliance to drug therapy. Rohatgi D; Lal A J Assoc Physicians India; 1998 May; 46(5):462-4, 467. PubMed ID: 11273292 [No Abstract] [Full Text] [Related]
6. Medication compliance as a feature in drug development. Kastrissios H; Blaschke TF Annu Rev Pharmacol Toxicol; 1997; 37():451-75. PubMed ID: 9131261 [TBL] [Abstract][Full Text] [Related]
7. Intention-to-treat has implications for study planning and execution, not just subject retention and follow-up. Hodges JS J Clin Periodontol; 2008 Aug; 35(8):683-4. PubMed ID: 18727742 [No Abstract] [Full Text] [Related]
8. Hair analysis: a worthless tool for therapeutic compliance monitoring. Tracqui A; Kintz P; Mangin P Forensic Sci Int; 1995 Jan; 70(1-3):183-9. PubMed ID: 7860030 [TBL] [Abstract][Full Text] [Related]
9. A note on 'The method of handling non-compliance in clinical trials suggested by Sato/Matsuyama'. Sjölander A Stat Med; 2008 Aug; 27(19):3920-4. PubMed ID: 18407577 [No Abstract] [Full Text] [Related]
10. [Therapeutic compliance]. Tomas M Rev Med Brux; 1998 Feb; 19(1):A49-50. PubMed ID: 9553457 [No Abstract] [Full Text] [Related]
11. Peak expiratory flow rate processed electronically. Kidd RJ; Kolbe J; Cochrane GM N Z Med J; 1993 Dec; 106(969):529-30. PubMed ID: 8183499 [No Abstract] [Full Text] [Related]
12. How should we measure medication adherence in clinical trials and practice? Borrego ME; Short J; Gupchup G; Naik R; Cuellar D J Am Pharm Assoc (2003); 2006; 46(4):420, 423. PubMed ID: 17517558 [No Abstract] [Full Text] [Related]
13. Design and analysis of controlled clinical trials in rheumatic diseases. Williams HJ; Reading JC; Ward JR Clin Rheum Dis; 1983 Dec; 9(3):499-514. PubMed ID: 6606530 [TBL] [Abstract][Full Text] [Related]
14. Adherence, the fourth dimension in the geometry of dermatological treatment. Nolan BV; Feldman SR Arch Dermatol; 2009 Nov; 145(11):1319-21. PubMed ID: 19917965 [No Abstract] [Full Text] [Related]
15. Does self-measurement of blood pressure improve patient compliance in hypertension? Edmonds D; Foerster E; Groth H; Greminger P; Siegenthaler W; Vetter W J Hypertens Suppl; 1985 Apr; 3(1):S31-4. PubMed ID: 3870467 [TBL] [Abstract][Full Text] [Related]
20. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Straka RJ; Fish JT; Benson SR; Suh JT Pharmacotherapy; 1997; 17(1):126-32. PubMed ID: 9017773 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]